Mabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311

▤ Summary

Mabwell received IND clearance from China’s NMPA for its LILRB4/CD3-targeting bispecific antibody 6MW5311. The candidate is intended to treat hematologic malignancies including AML, CMML, and multiple myeloma. Mabwell says the molecule uses a 2+1 asymmetric design to improve tumor selectivity, efficacy, and safety. The company also notes that the program already cleared FDA review for clinical trials, making it the first LILRB4/CD3 TCE drug candidate globally to reach this stage.

▦ Linked Companies